Publication Name	World Journal of Biological Chemistry
Manuscript ID	9046
Country	United States

Received	2014-01-18 18:13
Peer-Review Started	2014-01-18 20:02
To Make the First Decision	2014-02-13 16:18
Return for Revision	2014-02-20 23:51
Revised	2014-03-12 12:48
Second Decision	2014-05-14 16:29
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2014-05-14 16:42
Articles in Press	2014-05-23 08:59
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-08-29 15:16
Publish the Manuscript Online	2014-09-11 10:03

ISSN	1949-8454 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Cell Biology
Manuscript Type	Topic Highlights
Article Title	In 2014, can we do better than CA125 in the early detection of ovarian cancer?
Manuscript Source	Invited Manuscript
All Author List	Joshua G Cohen, Matthew White, Ana Cruz and Robin Farias-Eisner
Funding Agency and Grant Number
Corresponding Author	Robin Farias-Eisner M.D., Ph.D. UCLA Department of Obstetrics and Gynecology Peter Morton Medical Building 200 Medical Plaza, Suite 220 Los Angeles, CA 90095 Phone: (310) 206-8914 Fax: (310) 206-2057 Email address: RFEisner@mednet.ucla.edu
Key Words	ovarian cancer; screening; biomarker; detection; diagnostic imaging; proteomics; adnexal mass
Core Tip	Ovarian cancer is a lethal gynecologic malignancy with greater than 70% of women presenting with advanced stage disease. Despite new treatments, long term outcomes have not significantly changed in the past 30 years with the five-year overall survival remaining between 20 and 40% for stage III and IV disease. In contrast patients with stage I disease have a greater than 90% five-year overall survival. Detection of ovarian cancer at an early stage would likely have significant impact on mortality rate. Screening biomarkers discovered at the bench have not translated to success in clinical trials. Existing screening modalities have not demonstrated survival benefit in completed prospective trials. Advances in high throughput screening are making it possible to evaluate the development of ovarian cancer in ways never before imagined. Data in the form of human “–omes” including the proteome, genome, metabolome, and transcriptome are now available in various packaged forms. With the correct pooling of resources including prospective collection of patient specimens, integration of high throughput screening, and use of molecular heterogeneity in biomarker discovery, we are poised to make progress in ovarian cancer screening. This review will summarize current biomarkers, imaging, and multimodality screening strategies in the context of emerging technologies.
Publish Date	2014-09-11 10:03
Citation	Cohen JG, White M, Cruz A, Farias-Eisner R. In 2014, can we do better than CA125 in the early detection of ovarian cancer? World J Biol Chem 2014; 5(3): 286-300
URL	http://www.wjgnet.com/1949-8454/full/v5/i3/286.htm
DOI	http://dx.doi.org/10.4331/wjbc.v5.i3.286

Full Article (PDF)	WJBC-5-286.pdf
Full Article (Word)	WJBC-5-286.doc
Manuscript File	9046-Review.doc
Answering Reviewers	9046-Answering reviewers.pdf
Copyright License Agreement	9046-Copyright assignment.pdf
Peer-review Report	9046-Peer review(s).pdf
Scientific Editor Work List	9046-Scientific editor work list.pdf